- $19.39m
- $18.53m
- $0.07m
Brief: Lucid Diagnostics says Shaun M. O'neil Will Now Serve As President And Chief Operating Officer
Brief: Lucid Diagnostics Launches EsoGuard Esophageal DNA Test
U.S. RESEARCH ROUNDUP-Aerovironment, Hubspot, Oracle
PAVmed Inc reports results for the quarter ended in June - Earnings Summary
PAVmed Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: PAVmed And Lucid's Chairman And CEO Lishan Aklog Testifies At U.S. House Of Representatives Energy And Commerce Committee
Brief: PAVmed Receives 180-Day Extension To Regain Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP- Kenvue, Universal Health Services, Workday
PAVmed Inc reports results for the quarter ended in March - Earnings Summary
Brief: Pavmed Inc - QTRLY Non-GAAP Adjusted Loss Per Share $0.10
PAVmed Inc expected to post a loss of 24 cents a share - Earnings Preview
PAVmed Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Lucid Diagnostics Says Qtrly Loss Per Share $0.47
Brief: Lucid Diagnostics Provides Business Update And Q4 And Full Year 2022 Financial Results
PAVmed Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: PAVmed Says On Feb 14, Lucid Diagnostics Entered Into Agreement With ResearchDx
Brief: PAVmed And Lucid Diagnostics Provide Strategic Business Update
Brief: PAVmed Receives Notice From Nasdaq That Co Will Be Afforded Until June 27, 2023 To Regain Compliance
Brief: Pavmed Partners With Novosound On Ultrasound Imaging Technology